Read Our Recent News
Gary Cook won 2nd Oral Prize of British Nuclear Medicine Society
Date: April 1st-3rd, 2019 Gary Cook won 2nd Oral Prize of British Nuclear Medicine Society London, UK, April 1st-3rd, 2019. Gary Cook, scientific advisor of NanoMab presented 99mTc-NM-01 clinical data at the annual meeting of British Nuclear Medicine Society (BNMS) and was awarded with 2nd Oral Prize for his presentation ‘Imaging Programmed Cell Death Ligand-1 (PDL1) Expression in Non-Small Cell Lung Cancer with 99mTc anti PDL1 sdAb SPECT’. 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and [...]
NanoMab Publishes Clinical Research Paper on Journal of Nuclear Medicine
Date: Feb 22nd, 2019 NanoMab Publishes Clinical Research Paper on Journal of Nuclear Medicine Shanghai, China, February 22nd, 2019. NanoMab published its FIH data for the first 16 patients of 99mTc-NM-01 on Journal of Nuclear Medicine (JNM), titled ‘Early phase I study of a 99mTc labeled anti-PD-L1 single domain antibody in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung cancer’. 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression [...]
NanoMab Enters into Agreement with Guy’s and St Thomas’ NHS Foundation Trust for Investigator Initiated Study
Date: Feb 7th, 2019 NanoMab Enters into Agreement with Guy’s and St Thomas’ NHS Foundation Trust for Investigator Initiated Study London, UK, February 7th, 2019. NanoMab announced a collaboration with Guy’s and St Thomas’ NHS Foundation Trust on the investigator-initiated study for 99mTc-NM-01. The primary objective is to assess the change in PD-L1 expression in relation to immunotherapy in NSCLC and melanoma patients. 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression [...]
NanoMab and King’s College London to Collaborate on Next Generation One Step Radiolabelling
Date: Sep 12th, 2018 NanoMab and King’s College London to Collaborate on Next Generation One Step Radiolabelling Shanghai, China, September 12th, 2018. NanoMab announced a collaboration with the School of Biomedical Engineering and Imaging Sciences, King’s College London for the development of next generation single step radiolabelling for 99mTc/188Re.
NanoMab and LifeArc to Collaborate on Camelid Single Domain Antibody Humanization
Date: Aug 2nd, 2018 NanoMab and LifeArc to Collaborate on Camelid Single Domain Antibody Humanization Shanghai, China, August 2nd, 2018. NanoMab announced a collaboration with LifeArc (previously known as MRCT) for the humanization of camelid single domain antibody NM-02.
NanoMab Announces First NSCLC Patient Dosed in FIH of 99mTc-NM-01
Date: March 30th, 2018 NanoMab Announces First NSCLC Patient Dosed in FIH of 99mTc-NM-01 Shanghai, China, March 30th, 2018. NanoMab today announced dosing of the first patients for its FIH of 99mTc-NM-01 in patients with non-small cell lung cancer at SGH. 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression in patients before or during immuno-oncology treatment.